Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
search results for:
dealforma
Search
Inside the race to make psychedelics 'mainstream medicines'
4 years ago
R&D
In Focus
Biopharma has hyped AI for years. But as the first trials get underway, experts try to manage expectations
4 years ago
AI
In Focus
Latest news on Covid vaccine delay for kids; Door slammed shut for China-only data; Eric Lander is out; Looking back ...
4 years ago
Weekly
The 2022 top 100 biopharma investors: A look back on boom times
4 years ago
Financing
Deals
Latest news on Pfizer's $3B+ JAK1 win; Pacts over M&A at #JPM22; 2021 by the numbers; Biogen's Aduhelm reckoning; The ...
4 years ago
Weekly
Biopharma dealmakers reflect on last year's shifts in the market, as they gear up for another 'active' year ahead
4 years ago
Deals
#JPM22 - Dealmaking in 2022: What's Big Pharma looking for and what is it willing to pay?
4 years ago
Deals
Sofinnova hauls in $548M to build and scale startups — as European VCs step up their biopharma game
4 years ago
Financing
Latest news: Another Alzheimer's 'breakthrough'?; GSK decamps from iconic HQ; Red light in off-the-shelf CAR-T; ...
4 years ago
Weekly
Another three biotechs are set to debut on Nasdaq as combined industry raise tops $14B
4 years ago
Financing
OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO
4 years ago
Financing
Is the biotech boom starting to fade? The roaring ‘20s starts to look a little fatigued. Plus: Top 5 deals, IPOs, ...
4 years ago
Deals
Bioregnum
Biotech grieves over Tachi’s passing; $3 trillion mirage?; Sanofi has a new Pompe drug; and more
4 years ago
Weekly
Bayer nabs star biotech Vividion with a $2B buyout and an ‘arms-length’ pact, pulling a partner out of the IPO ...
4 years ago
Deals
Sanofi buys mRNA player Translate Bio for $3.2B. And the price fits a popular range for biotech M&A
4 years ago
Deals
How one startup foretold the neuroscience renaissance after '50 years of shitshow'
4 years ago
R&D
In Focus
Biogen pressed against the wall as more stakeholders side against Aduhelm; Prime time for CRISPR 3.0?; and more
4 years ago
Weekly
IPOs and venture investing rock on in Q2 as SPAC attack takes a break. But what happened to the deals and M&A?
4 years ago
Bioregnum
First page
Previous page
1
2
3
4
5
6
7
Next page
Last page
latest
Most read
Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays
4 days ago
People
Pharma
Biopharma’s highest-paid CEOs; John Carroll’s Q2 analysis; Merck to buy Verona Pharma for $10B; and more
21 hours ago
Weekly
Karyopharm cuts 20% of staff as it looks at 'strategic alternatives' or raising cash
Yesterday
Financing
European regulators lift restriction on Valneva’s chikungunya vaccine
Yesterday
Pharma
FDA+
Novartis dealt a blow in patent fight to block Entresto generics
Yesterday
Pharma
Law
see latest stream
